This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: A81.1 (Subacute sclerosing panencephalitis) | Special Copayment Reduction: V282 (severe intractable disease — prion and related diseases, 10% copayment for 5 years after registration) |
| B. Synonyms | Dawson inclusion body encephalitis, Van Bogaert sclerosing leukoencephalopathy, subacute sclerosing panencephalitis, SSPE |
| C. Adult onset | Low likelihood of first onset in adulthood — most cases begin in adolescence after a latent period of several years to 15 years following primary measles infection in childhood (ages 2–10); cases beginning in early adulthood (20s) are rarely reported but account for less than 10% of all patients. |
| 1. History | 1933 Dawson first describes brain inclusion bodies → 1945 Van Bogaert describes the sclerosing leukoencephalopathy type → 1967 association with measles virus established → 1969 Connolly discovers virus-specific antibodies → after the measles vaccine, incidence falls sharply in developed countries. |
| 2. Causes | Persistent infection of the brain by measles virus (Measles morbillivirus). The virus persists in the central nervous system in a defective form and evades immunity. Risk is particularly high with primary measles infection before age 2. |
| 3. Genetics | No single-gene abnormality. Some studies suggest that HLA type and immune response gene polymorphisms influence susceptibility, but this has not been established. Defective mutations of the viral M protein itself are the key to persistent infection. |
| 4. General epidemiology | 5–10 per 100,000 before the measles vaccine. Incidence in developed countries decreased by more than 95% after introduction of the measles vaccine. 2–3 times more frequent in boys. In Korea, it has fallen to a virtually extremely rare level since MMR vaccination became established. |
| 5. Pathophysiology | Measles virus M protein mutation → persistent infection in neurons and glial cells → impaired viral transmission (only cell-to-cell spread possible) → immune response in the brain (Radermecker complexes) → widespread brain neuronal damage. |
| 6. Symptoms | Stage 1: behavioral and personality changes, decline in school performance. Stage 2: myoclonus, epileptic seizures. Stage 3: movement abnormalities, visual abnormalities, worsening cognitive decline. Stage 4: vegetative state, autonomic abnormalities. Mean duration of illness 1–3 years. |
| 7. Signs | EEG: Radermecker complex (periodic high-amplitude discharges at 4–15-second intervals). CSF: elevated anti-measles IgG antibody, hypergammaglobulinemia. MRI: increased T2 signal in subcortical white matter and basal ganglia. CSF measles antibody titer (>1:4) has diagnostic value. |
| 8. Screening | No screening of the general population. In children with unexplained encephalopathy, seizures, or cognitive decline, measurement of serum and CSF measles antibody titers serves as practical screening. Perform immediately when clinically suspected in unvaccinated children. |
| 9. Diagnosis | Clinical criteria: characteristic EEG + elevated CSF anti-measles IgG + typical clinical course. Confirmation: brain biopsy (inclusion bodies, measles antigen) is often unnecessary. The revised diagnostic criteria of Jabbour (1969) are used. |
| 10. Treatment | No curative treatment. Isoprinosine (inosiplex) alone or combined with intrathecal/intravenous interferon alfa has been tried to slow progression. Anticonvulsants for seizure control. Palliative and supportive treatment is the mainstay. |
| 11. Prognosis | Poor prognosis. 85–95% die within 1–3 years of diagnosis. Spontaneous remission 5–10% and chronic progression 10–20% are reported. Survival is prolonged in some with early diagnosis and isoprinosine treatment. Complete recovery is very rare. |
| 12. Prevention | MMR (measles-mumps-rubella) vaccination is the only effective means of prevention. Complete the first dose at 12–15 months of age and the second dose at 4–6 years. Maintaining measles herd immunity is key to preventing SSPE. |
| 13. References | Garg RK. Subacute sclerosing panencephalitis. Postgrad Med J. 2002 … and 9 other papers |
The history of subacute sclerosing panencephalitis (SSPE) starts in 1933, when the American neuropathologist James Dawson observed characteristic intranuclear inclusion bodies in the brain tissue of a child patient with progressive brain inflammation and described it as 'inclusion body encephalitis'. Dawson presumed that these inclusion bodies might suggest viral infection, but the etiology had not yet been elucidated at that time.
In 1945, the Belgian neurologist Ludo Van Bogaert separately described patients with a similar clinical course as 'sclerosing leukoencephalopathy', which was later confirmed to be the same disease as Dawson's description. As clinical and pathological observations accumulated in the 1950s–60s, the unified name 'subacute sclerosing panencephalitis' was established.
Decisive elucidation of the etiology came in 1967–1969. In 1967, Connolly et al. and Shaw et al. independently found high-titer neutralizing antibodies to measles virus in the serum and cerebrospinal fluid of SSPE patients, and in 1969 nucleocapsid structures resembling measles virus were observed by electron microscopy in SSPE brain tissue. Subsequently, the measles virus genome was directly detected in SSPE lesions by virus culture, immunofluorescence, and molecular biological techniques, establishing measles virus as the cause of SSPE.
The most important epidemiological turning point was the development of the live measles vaccine in 1963 and the subsequent spread of the combined MMR vaccine. Since the 1960s, when measles vaccination began in the United States, the incidence of SSPE has decreased by more than 90% over several decades, and it has now become an extremely rare disease in developed countries. In Korea as well, SSPE occurrence has reached a virtually eradicated level since the introduction of the second MMR dose in 1997. However, sporadic cases are still reported in some developing countries with low measles vaccination coverage.
SSPE is a chronic progressive encephalitis caused by measles virus (Measles morbillivirus, former name: Measles virus) causing persistent infection in the central nervous system. Measles virus is a single-stranded negative-sense RNA virus belonging to the genus Morbillivirus of the family Paramyxoviridae.
The key mechanism by which the virus persists in the central nervous system for years to decades in SSPE is related to mutations of the viral M (matrix) protein. In normal measles infection, the M protein is essential for viral assembly and budding out of the cell. In SSPE virus, excessive point mutations (hypermutation, especially A-to-G transitions) accumulate in the M protein gene, causing dysfunction or deficiency. As a result, the virus cannot be released out of the cell and depends only on direct cell-to-cell spread, spreading slowly within the brain while evading antibody neutralization by the immune system.
The main risk factor for SSPE is early measles infection before age 2. In children who contract measles before age 2, the risk of SSPE is about 10–16 times higher than at later ages. This is interpreted to be because the immature immune system cannot completely clear the virus and allows latency within the central nervous system. The reason for the 2–3 times higher incidence in boys has not been fully elucidated, but is presumed to be related to sex-related differences in immune response.
Measles vaccine virus, unlike wild-type measles virus, is known not to cause SSPE. There are extremely rare reports of SSPE after MMR vaccination, but epidemiological analyses have confirmed that MMR vaccination actually reduces the risk of SSPE by more than 10-fold.
SSPE is not a specific single-gene disease but an acquired neurological disease caused by persistent measles virus infection. Therefore it does not follow Mendelian inheritance and is not directly inherited from parents to children. However, there are studies suggesting that the host's genetic background influences susceptibility to persistent central nervous system infection with measles virus.
The possibility that immune-related gene polymorphisms are involved in SSPE susceptibility has been studied. There are reports that HLA (human leukocyte antigen) type, particularly specific HLA-DR alleles, may be associated with the frequency of SSPE occurrence, but a reproducible specific HLA type has not yet been established. There are small studies suggesting that polymorphisms of interferon response pathways, genes related to NK cell activity, and complement system genes may be involved in susceptibility.
More important from the viewpoint of viral genetics are the characteristics of the SSPE virus itself. Viruses isolated from SSPE patients have markedly accumulated hypermutation of the M protein gene compared with wild-type measles virus. In particular, excessive A-to-I (I is inosine) RNA editing by the ADAR (adenosine deaminase acting on RNA) enzyme occurs, and the function of the M protein is lost. This RNA editing mechanism is the key to making the virus a 'defective persistent-infection virus'. In addition, mutations in the cytoplasmic domain of the fusion (F) protein promote direct cell-to-cell spread, and mutations of the H (hemagglutinin) protein contribute to immune evasion.
Familial SSPE is extremely rare, and most cases are sporadic. Genetic counseling is not needed for SSPE itself, and the key to prevention is measles vaccination.
The incidence of SSPE varies greatly with measles virus epidemics and vaccination coverage. Before the introduction of the measles vaccine (before the 1960s), the incidence in the United States was estimated at about 5–10 per 1 million measles infections, but after expansion of MMR vaccination it fell sharply in developed countries and is now at an extremely rare level of 0.03–0.1 per 100,000 or less.
By age, onset is concentrated between ages 5 and 15, and the mean latent period from primary measles infection to SSPE onset is 6–8 years (range: 1–20 years). It occurs 2–3 times more often in boys than in girls, and a history of measles infection before age 2 is the strongest risk factor. In developing countries, particularly the Middle East, South Asia, and Africa, considerable incidence is still reported owing to reduced vaccination coverage.
In Korea, SSPE cases were reported sporadically before 1985, but with the introduction of the second MMR dose (before elementary school entry) in 1997 and the subsequent maintenance of high vaccination coverage, new cases have virtually disappeared. Since the 2000s, most domestically reported cases have been in adults who contracted measles before measles vaccination became universal, or in immigrants who returned after being infected with measles abroad.
When measles herd immunity is maintained at 95% or higher, measles-related complications, including SSPE, are also effectively prevented. Concern has recently been raised that as measles vaccination coverage falls below 95% in some countries, SSPE incidence may also rise again along with measles resurgence.
The pathophysiology of SSPE is explained by a complex interaction between persistent measles virus infection of the central nervous system and immune-mediated neural damage. The route by which the virus invades the brain during the initial measles infection has not been clearly established, but a Trojan horse mechanism, in which infected monocytes or lymphocytes cross the blood-brain barrier and deliver the virus into the brain, is strongly proposed.
Once measles virus has entered the central nervous system, it infects neurons and glial cells and cannot form normal viral particles because of M protein mutations. Instead, viral components replicated within the cell spread directly to adjacent cells through cell-cell junctions and slowly spread throughout the brain. In this process, the virus is not exposed to antibodies in the blood, allowing immune evasion.
From an immunopathological viewpoint, the reason the virus is not cleared even though high-titer anti-measles antibodies are detected in serum and CSF is that the virus is not exposed outside cells. CD8+ cytotoxic T lymphocytes are also not sufficiently recruited because of the blood-brain barrier, and the cell-mediated immune response against persistently infected neurons contributes to neural damage. In the SSPE brain, perivascular infiltration of plasma cells and lymphocytes and gliosis are characteristic.
The Radermecker complex observed on electroencephalography (EEG) is a cluster of high-amplitude abnormal waves repeating periodically (at 4–15-second intervals), reflecting widespread neuronal hyperexcitability and synchronized discharges. This is interpreted as the result of virus-mediated damage to neuronal networks and gliosis causing an abnormal excitation-inhibition balance.
The clinical course of SSPE is traditionally divided into 4 stages (stage I–IV), and mostly progresses over months to years. The total duration of illness averages 1–3 years, but varies from rapidly progressing cases (weeks) to chronic courses lasting more than 10 years.
Stage 1 (behavioral and cognitive change phase): As the earliest symptoms, personality change (becoming aggressive or excessively introverted), decline in school performance, reduced concentration, and memory impairment appear. Because symptoms are nonspecific, SSPE is rarely diagnosed at this stage, and it may be mistaken for a learning disorder or psychological problem. Duration is several months.
Stage 2 (myoclonus and seizure phase): Characteristic rhythmic myoclonus appears. Sudden generalized or segmental muscle contractions repeat periodically at 5–10-second intervals, which corresponds to the Radermecker complex on EEG. Seizures (epilepsy), ataxia, and visual abnormalities (visual field defects, cortical visual impairment, macular lesions) also appear at this stage.
Stage 3 (motor disorder and autonomic dysfunction phase): Motor function declines rapidly, leading to inability to walk and dysphagia. Rigidity, dystonia, and atypical movement abnormalities accompany. Visual impairment worsens and cognitive function is almost lost. Autonomic dysfunction such as abnormal sweating and impaired thermoregulation becomes evident.
Stage 4 (vegetative state phase): Progresses to loss of consciousness or a minimally conscious state, with decerebrate posturing, respiratory failure, and recurrent infections (pneumonia, etc.). Most patients die within 1–2 years at this stage. Spontaneous remission or a chronic stable stage is observed in some patients, but complete recovery is extremely rare.
The most important objective signs in the diagnosis of SSPE are the characteristic electroencephalography (EEG) findings and cerebrospinal fluid (CSF) examination.
EEG findings: The Radermecker complex is an EEG finding that is almost pathognomonic after SSPE stage 2, a cluster of high-amplitude (>200 μV) 3–5 Hz polymorphic delta waves repeating periodically at 4–15-second intervals. Myoclonus accompanies clinically when this discharge occurs. Early on it appears only during sleep, but as the disease progresses it is observed persistently even during wakefulness.
CSF findings: CSF protein is normal or mildly elevated, and the cell count is normal or shows a mild lymphocytosis. The most diagnostically important finding is a marked elevation of anti-measles IgG antibody in the CSF, characterized by a reversed serum:CSF antibody ratio (gold ratio; CSF relatively higher than serum). CSF oligoclonal IgG bands are detected on immunoelectrophoresis. The CSF measles antibody titer (depending on the measurement method, ≥1:4 or >1:16) forms part of the diagnostic criteria.
MRI findings: Early on it is normal or shows only subtle changes, but as the disease progresses, increased T2/FLAIR signal appears in the subcortical and deep white matter, and lesions spread to the basal ganglia, thalamus, and brainstem. Cortical atrophy and reduced brain volume become evident in the late stage. Brain tissue biopsy shows Cowdry type A intranuclear inclusion bodies and plasma cell and lymphocyte infiltration, but biopsy is unnecessary when clinical diagnosis is possible.
Serum tests: Serum anti-measles IgG antibody is detected at a markedly higher titer than in normal persons. Even with a history of measles vaccination, much higher antibody titers are maintained in SSPE patients.
There is currently no systematic screening program for SSPE in the general population. This is because the disease itself is extremely rare (in countries where measles vaccination is widespread) and a cost-effective screening strategy is difficult to define.
The approaches that practically contribute to early detection of SSPE are as follows. First, early testing based on clinical suspicion is the key. In children and adolescents with progressive cognitive decline or behavioral change of unknown cause, especially when measles vaccination is incomplete or there is a history of measles infection, serum and CSF anti-measles antibody titers should be measured early. Second, SSPE must be included in the differential diagnosis list in patients with unexplained periodic myoclonus or EEG abnormalities.
Educating parents of unvaccinated or incompletely vaccinated children about the possibility of SSPE and emphasizing recognition of early symptoms also serves an indirect screening function. Some experts recommend measuring anti-measles antibody in children with abnormal behavior or cognitive decline in measles-endemic areas.
Diagnosis of SSPE is made on the basis of clinical criteria (modified Jabbour criteria), and most cases can be confirmed by a combination of specific EEG, CSF, and imaging findings.
Clinical diagnostic criteria (modified international criteria): Two or more of the following: ① progressive neurological abnormality (cognitive, behavioral, or motor impairment); ② characteristic EEG (Radermecker complex); ③ abnormally elevated serum or CSF anti-measles antibody (serum >1:256, CSF >1:4, or elevated CSF:serum index); ④ detection of inclusion bodies or measles antigen/genes on brain biopsy/autopsy.
Stepwise testing: In step 1, serum anti-measles IgG antibody is measured, and a marked elevation (10 times or more the usual measles immunity level) strongly suggests SSPE. In step 2, CSF examination is performed to confirm CSF anti-measles IgG and oligoclonal IgG bands. In step 3, the Radermecker complex is confirmed on EEG, and in step 4, brain MRI is performed to evaluate the distribution of characteristic white matter lesions.
Brain biopsy is considered when clinical and laboratory findings are atypical or other diagnoses must be excluded. Cowdry type A intranuclear inclusion bodies, neuronal loss, astrocytosis, and plasma cell and lymphocyte infiltration are identified in the tissue, and measles virus antigen/genes are detected by immunohistochemistry or PCR. Differential diagnosis includes encephalitis (herpes simplex, autoimmune) and noninfectious progressive neurological diseases (lysosomal storage disease, mitochondrial disease).
To date there is no curative treatment for SSPE, and the goal of treatment is to slow the rate of disease progression and relieve symptoms.
Isoprinosine (inosiplex) is a drug with immunomodulatory and antiviral effects and is the most widely used in SSPE. There are reports that oral administration (100 mg/kg/day, maximum 3–4 g/day) delays disease progression and induces remission in some patients. Randomized controlled trials are lacking, but retrospective studies and case reports suggest a survival-prolonging effect. It is used as standard treatment in several countries, including Korea, and long-term administration is required.
Interferon alfa (IFN-α) combination therapy: Combining intraventricular or intrathecal interferon alfa with isoprinosine has been tried in some cases. Intraventricular administration is performed through a ventriculoperitoneal shunt (VPS) and can bypass the problem of blood-brain barrier penetration. There are reports from small studies that combination therapy gave better results than isoprinosine alone, but its use is limited because of the invasiveness of the procedure and infection risk.
Anticonvulsants: Valproic acid, levetiracetam, clonazepam, and others are used for seizure control. Clonazepam or piracetam may help with myoclonus. Baclofen and others are used for generalized rigidity or dystonia.
Supportive and palliative treatment: Nutritional support (gastrostomy, nasogastric tube), pressure ulcer prevention, management of respiratory infections, and physical and occupational therapy are important for maintaining quality of life. Family support and involvement of a palliative care team are recommended.
The prognosis of SSPE is generally poor. When the course is observed without treatment after diagnosis, about 85–95% of patients die within 1–3 years of diagnosis, and the 5-year survival rate after onset is about 10–15%. In the fulminant form, death occurs within months.
Spontaneous remission is rarely reported (about 5–10%), and relapse after remission is also possible. In patients with a chronic stable course, progression may stop at a particular stage for several years. There are reports that isoprinosine treatment can significantly delay disease progression in some patients and prolong survival (an average of 1–2 additional years of survival), but cure is very rare.
Prognostic factors considered include age at onset (the younger, the worse), speed of the early clinical course (the faster, the worse), frequency of EEG discharges, and extent of MRI lesions. Early diagnosis and early isoprinosine administration may have a positive effect on the course in some patients.
In Korea, new cases are currently extremely rare, so most clinicians are unlikely to encounter actual SSPE patients. However, SSPE must be differentiated when unexplained neurological abnormality occurs in children of immigrants who have not received measles vaccination or in children with a history of visiting measles-endemic areas.
The only effective means of preventing SSPE is measles vaccination (MMR vaccine). By blocking measles virus infection itself, SSPE can be prevented at its source. Epidemiological studies have confirmed that MMR vaccination reduces the risk of measles infection by more than 95% and the risk of SSPE by more than 10-fold compared with before vaccination.
Standard vaccination schedule: According to the Korean national immunization recommendations, the first MMR dose is completed at 12–15 months of age and the second MMR dose at 4–6 years of age. When 2 doses are completed, the rate of protective serum antibody formation against measles is 99% or higher. MMR vaccination is recommended for adults who have no or uncertain measles antibody (born after 1957, with no history of 2 MMR doses and no history of measles illness).
Maintaining herd immunity: To block measles transmission, about 95% or more of the population must be immune, and when this level is maintained, all measles-related complications, including SSPE, are suppressed. Reduced vaccination coverage due to anti-vaccination movements is the biggest risk factor for the reappearance of SSPE.
Protection of infants under 2 years: Infants before the first MMR dose (under 12 months) have the highest risk of SSPE if infected with measles, so it is important to protect infants indirectly by completing vaccination of surrounding adults and siblings (cocoon strategy). Early MMR vaccination for infants aged 6–11 months during a measles outbreak (with additional doses per the standard schedule afterward) may also be considered.
Garg RK. Subacute sclerosing panencephalitis. Postgrad Med J. 2002;78(916):63-70. DOI: 10.1136/pmj.78.916.63. PMID: 11807193.
Anlar B. Subacute sclerosing panencephalitis and chronic viral encephalitis. Handb Clin Neurol. 2014;123:501-514. DOI: 10.1016/B978-0-444-53488-0.00024-8. PMID: 25015506.
Gutierrez J, Issacson RS, Koppel BS. Subacute sclerosing panencephalitis: an update. Dev Med Child Neurol. 2010;52(10):901-907. DOI: 10.1111/j.1469-8749.2010.03717.x. PMID: 20561004.
Makhortova NR, Askovich P, Patterson CE, et al. Neurokinin-1 enables measles virus trans-synaptic spread in neurons. Virology. 2007;362(1):235-244. DOI: 10.1016/j.virol.2007.01.017. PMID: 17303211.
Wendorf KA, Winter K, Zipprich J, et al. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. Clin Infect Dis. 2017;65(2):226-232. DOI: 10.1093/cid/cix273. PMID: 28379399.
Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol. 2007;36(6):1334-1348. DOI: 10.1093/ije/dym207. PMID: 17875578.
Prashanth LK, Taly AB, Sinha S, et al. Long term survival in subacute sclerosing panencephalitis: an enigma. Brain Dev. 2006;28(7):447-452. DOI: 10.1016/j.braindev.2006.01.005. PMID: 16621409.
Gascon GG; International Consortium on SSPE. Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE). J Child Neurol. 2003;18(12):819-827. DOI: 10.1177/08830738030180120801. PMID: 14736079.
Saha V, John TJ, Mukundan P, et al. High incidence of subacute sclerosing panencephalitis in South India. Epidemiol Infect. 1990;104(1):151-156. DOI: 10.1017/s0950268800054601. PMID: 2307492.
Young VA, Rall GF. Making it to the synapse: measles virus spread in and among neurons. Curr Top Microbiol Immunol. 2009;330:3-30. DOI: 10.1007/978-3-540-70617-5_1. PMID: 19203103.